Published : Dec-2019
No. of Pages : 104
1.1 List of Tables
1.2 List of Figures
2 Seasonal Influenza Vaccines: Executive Summary
2.1 Modest Growth Expected for the Seasonal Influenza Vaccine APAC Market over the Forecast Period from 2018-2028
2.2 Transition from Trivalent to Quadrivalent Influenza Vaccines in China and India, Launch of Specialized Vaccines in Japan
2.3 Higher Seasonal Influenza Vaccination Rates and Better Vaccine Efficacy Are Major Unmet Needs
2.4 Quadrivalent Inactivated and Live-Attenuated Influenza Vaccines Will Launch in China and India, Plant-Based Vaccine in Japan
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Disease Seasonal Influenza (2018-2028)
5.6 Discussion
6 Disease Management in APAC
6.1 Diagnosis and Treatment Overview
6.2 China
6.3 India
6.4 Japan
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment in APAC
8.1 Overview
8.2 Immunization Programs Including the Elderly and Children
8.3 Enhanced Vaccine Efficacy in High-Risk Groups
8.4 Public Opinion of Seasonal Influenza Vaccines: Awareness, Hesitancy, and Skepticism
8.5 Vaccines Leveraging Improved Manufacturing Technologies and Featuring Broader Influenza Strain Coverage
9 Pipeline Assessment in APAC
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players in APAC
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Portfolio Assessment
11 Market Outlook in APAC
11.1 Global Markets
11.2 China
11.3 India
11.4 Japan
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - KOLs Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
List of Tables
Table 1: Seasonal Influenza Vaccines: Key Metrics in the 3GM in APAC
Table 2: Influenza Symptoms
Table 3: Risk Factors and Comorbidities for Seasonal Influenza
Table 4: National Vaccination Recommendations for Seasonal Influenza
Table 5: Main Vaccines and Targeted Population for Routine Administration in China
Table 6: Main Vaccines and Targeted Population for Routine Administration in India
Table 7: Main Vaccines and Targeted Population for Routine Administration in Japan
Table 8: Leading Vaccines for Seasonal Influenza, 2019
Table 9: Takeda's Disease Portfolio Assessment, 2019
Table 10: Denka Seiken's Disease Portfolio Assessment, 2019
Table 11: Mitsubishi Tanabe's Disease Portfolio Assessment, 2019
Table 12: Sanofi's Disease Portfolio Assessment, 2019
Table 13: Seqirus' Disease Portfolio Assessment, 2019
Table 14: Serum Institute's Disease Portfolio Assessment, 2019
Table 15: Cadila's Disease Portfolio Assessment, 2019
Table 16: Sinovac's Disease Portfolio Assessment, 2019
Table 17: Medicago's Disease Portfolio Assessment, 2019
Table 18: Other Companies' Disease Portfolio Assessment, 2019
Table 19: Seasonal influenza Vaccine Market - Global Drivers and Barriers, 2018-2028
Table 20: Key Events Impacting Sales for Seasonal influenza Vaccines in China, 2018-2028
Table 21: Seasonal Influenza Vaccine Market - Drivers and Barriers in China, 2018-2028
Table 22: Key Events Impacting Sales for Seasonal Influenza Vaccines in India, 2018-2028
Table 23: Seasonal Influenza Vaccines Market - Drivers and Barriers in India, 2018-2028
Table 24: Key Events Impacting Sales for Seasonal Influenza Vaccines in Japan, 2018-2028
Table 25: Seasonal Influenza Vaccines Market - Global Drivers and Barriers in Japan, 2018-2028
Table 26: Key Historical and Projected Launch Dates for Seasonal Influenza Vaccines
Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: APAC 3GM Sales Forecast by Country for Seasonal Influenza Vaccines in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in Seasonal Influenza Vaccines During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Prevention of Seasonal Influenza During the Forecast Period
Figure 4: Influenza Virus Structure
Figure 5: Diagnosed Incidence of Lab-Confirmed Seasonal Influenza, Men and Women, All Ages, Cases per 100,000 Population, 2018
Figure 6: 3GM, Sources Used and Not Used for Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
Figure 7: 3GM, Sources Used for Lab-Confirmed Seasonal Influenza Mortality
Figure 8: 3GM, Sources Used for Proportion of People Receiving Seasonal Influenza Vaccination
Figure 9: 3GM, Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018
Figure 10: 3GM, Age-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018, N
Figure 11: 3GM, Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, All Ages, 2018, N
Figure 12: 3GM, Lab-Confirmed Seasonal Influenza Mortality, Both Sexes, All Ages, 2018, N
Figure 13: 3GM, Age-Specific Cases of People Receiving Seasonal Influenza Vaccination, Both Sexes, All Ages, 2018, N
Figure 14: Unmet Needs and Opportunities in Seasonal Influenza Vaccination
Figure 15: Overview of the Development Pipeline for Seasonal Influenza Vaccines
Figure 16: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Seasonal Influenza in the 3GM During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for Seasonal Influenza Immunization During the Forecast Period
Figure 18: Analysis of the Company Portfolio Gap in Seasonal Influenza Vaccines During the Forecast Period
Figure 19: APAC (3GM) Sales Forecast by Country for Seasonal Influenza Vaccines in 2018 and 2028
Figure 20: Sales Forecast by Class for Seasonal Influenza Vaccines in China in 2018 and 2028
Figure 21: Sales Forecast by Class for Seasonal Influenza Vaccines in India in 2018 and 2028
Figure 22: Sales Forecast by Class for Seasonal Influenza Vaccines in Japan in 2018 and 2028
